CLINICAL TRIALS PROFILE FOR ETRIPAMIL

All Clinical Trials for etripamil

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02296190 ↗	Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm	Completed	Medpace, Inc.	Phase 2	2015-03-27	The primary objective of this study is to demonstrate the superiority of at least 1 dose of intranasal (IN) MSP-2017 (Etripamil) over placebo in terminating PSVT induced in an electrophysiology (EP) laboratory.
NCT02296190 ↗	Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm	Completed	Milestone Pharmaceuticals Inc.	Phase 2	2015-03-27	The primary objective of this study is to demonstrate the superiority of at least 1 dose of intranasal (IN) MSP-2017 (Etripamil) over placebo in terminating PSVT induced in an electrophysiology (EP) laboratory.
NCT03464019 ↗	Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE 301 [Part 1 and Part 2 (The RAPID Study)]	Recruiting	IQVIA Biotech	Phase 3	2018-06-18	This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etripamil NS self-administered by patients who experience an episode of paroxysmal ventricular tachycardia (PSVT) in an at-home setting. Part 1 comprised the conduct of the NODE-301 study up to the date of the adjudication of 150th positively adjudicated PSVT episode and Part 2 comprises the conduct of the NODE-301 study after the completion of Part 1. The RAPID Study (NODE-301 - Part 2) will enroll patients enrolled during Part 1 who had not dosed with the double-blind study drug, or had not discontinued the study before the adjudication of the 150th positively adjudicated PSVT episode in Part 1, and patients enrolled into the study following the completion of Part 1. Enrollment will continue until and for approximately 6 months after the date of the adjudication of the 180th positively adjudicated PSVT episode. The study will include the following visits: A Screening Visit, A Test Dose Randomization Visit, Monthly Follow-up Visits, A Randomized Treatment Period, A Randomized Treatment Period Follow-Up Visit, An Open-Label Treatment Period, and A Final Study Visit.
NCT03464019 ↗	Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE 301 [Part 1 and Part 2 (The RAPID Study)]	Recruiting	Medpace, Inc.	Phase 3	2018-06-18	This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etripamil NS self-administered by patients who experience an episode of paroxysmal ventricular tachycardia (PSVT) in an at-home setting. Part 1 comprised the conduct of the NODE-301 study up to the date of the adjudication of 150th positively adjudicated PSVT episode and Part 2 comprises the conduct of the NODE-301 study after the completion of Part 1. The RAPID Study (NODE-301 - Part 2) will enroll patients enrolled during Part 1 who had not dosed with the double-blind study drug, or had not discontinued the study before the adjudication of the 150th positively adjudicated PSVT episode in Part 1, and patients enrolled into the study following the completion of Part 1. Enrollment will continue until and for approximately 6 months after the date of the adjudication of the 180th positively adjudicated PSVT episode. The study will include the following visits: A Screening Visit, A Test Dose Randomization Visit, Monthly Follow-up Visits, A Randomized Treatment Period, A Randomized Treatment Period Follow-Up Visit, An Open-Label Treatment Period, and A Final Study Visit.

Clinical Trial Conditions for etripamil

Condition Name

Condition Name for etripamil
Intervention	Trials
Paroxysmal Supraventricular Tachycardia	6
Atrial Fibrillation	2
Healthy Chinese Subjects	1
Paroxysmal Supraventricular Tachycardia (PSVT)	1

Condition MeSH

Condition MeSH for etripamil
Intervention	Trials
Tachycardia, Ventricular	7
Tachycardia, Supraventricular	7
Tachycardia	7
Atrial Fibrillation	2

Clinical Trial Locations for etripamil

Trials by Country

Trials by Country for etripamil
Location	Trials
United States	85
Canada	17
Spain	3
China	3
Netherlands	2

Trials by US State

Trials by US State for etripamil
Location	Trials
Virginia	4
Texas	4
South Dakota	4
Ohio	4
Minnesota	4

Clinical Trial Progress for etripamil

Clinical Trial Phase

Clinical Trial Phase for etripamil
Clinical Trial Phase	Trials
PHASE3	1
Phase 3	5
Phase 2	3

Clinical Trial Status

Clinical Trial Status for etripamil
Clinical Trial Phase	Trials
Not yet recruiting	4
Recruiting	3
Completed	2

Clinical Trial Sponsors for etripamil

Sponsor Name

Sponsor Name for etripamil
Sponsor	Trials
Milestone Pharmaceuticals Inc.	10
Medpace, Inc.	3
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.	2

Sponsor Type

Sponsor Type for etripamil
Sponsor	Trials
Other	12
Industry	7

Etripamil: Clinical Trials Update, Market Analysis and Projection

Last updated: May 9, 2026

What is etripamil and how is it positioned in development?

Etripamil (also referred to as intravenous etripamil in clinical programs) is a cardiovascular drug candidate built around the pharmacology of verapamil for rate and rhythm control in acute and peri-procedural settings. The development strategy is aimed at improving clinical workflow and therapeutic controllability in conditions where conventional calcium channel blockers are used.

What do current clinical trials indicate?

No complete, reliable, up-to-date clinical-trials dataset is available in the provided information to generate a precise “as-of” update (trial identifiers, enrollment status, readouts, endpoints, and dates). Without that specific trial record, producing a definitive trials update would risk inaccuracies.

What is the current market definition and addressable scope?

A defensible market analysis depends on aligning etripamil’s intended use with specific, revenue-relevant segments (for example: acute rate control in atrial fibrillation, peri-procedural tachyarrhythmia management, or other verapamil-like indications). The required inputs include indication(s), geography, patient population sizing, comparator landscape, and expected route-of-administration and setting (ED, ICU, cath lab, inpatient telemetry). Those indication-specific and geography-specific details are not provided in the input.

What market data points are required to project revenues?

Revenue projection requires at least:

• Indication-specific addressable population
• Target dosing regimen (dose, frequency, duration)
• Expected penetration assumptions (share of treated patients, competitor displacement)
• Price assumptions (WAC or ASP, and payer coverage by setting)
• Uptake curve tied to trial outcomes and guideline inclusion

The input contains none of these.

How should investors and R&D teams frame etripamil’s commercial thesis?

Given only the drug name, the analysis cannot be completed to the standard required for business decisions. A credible commercial thesis must state:

• Which indication(s) etripamil targets
• What trial outcomes support differentiation
• Whether uptake is expected via guideline adoption or hospital protocol
• How clinicians integrate it against standard comparators
• What economic driver (speed of onset, controllability, safety profile, administration convenience) moves utilization

These claims require evidence from trial records and market access benchmarks.

---

Market projection framework (structure only, no numeric projections)

A revenue projection model for a cardiovascular infusion or acute-care agent typically uses:

1) Treated population

• Patients with the target condition in the target care setting
• Proportion eligible for intravenous therapy
• Proportion receiving calcium-channel blocker therapy (or specific comparator mix)

2) Penetration

• Uptake by guideline adoption or local protocol adoption
• Share gained from comparators (antiarrhythmics, beta blockers, calcium channel blockers)

3) Dose-based drug utilization

• Units per treated patient
• Average number of vials/ampoules per event
• Waste factor (if formulation constraints exist)

4) Pricing and reimbursement

• Net price proxy
• Site-of-care reimbursement dynamics (inpatient vs ED vs outpatient infusion)

5) Launch curve

• Ramp by safety data and protocol standardization
• Peak penetration scenario vs base case vs downside

Without etripamil’s indication, route, dosing regimen, and clinical differentiation, any numeric projections would be unsound.

---

Clinical and commercial due diligence checklist (what must be verified)

For etripamil, the minimum due diligence set for a numbers-based model includes:

Trial evidence package

• Phase (and any interim status) for each clinical study
• Primary endpoints and results (time-to-effect, rate control endpoints, conversion endpoints, safety endpoints)
• Comparator(s) used (verapamil, diltiazem, beta blockers, antiarrhythmics, placebo/standard of care)
• Population characteristics (AF subtype, peri-procedural context, hemodynamic inclusion/exclusion)
• Dosing schedule and administration workflow

Market access package

• Target care setting(s)
• Uptake pathway (guidelines vs hospital protocol)
• Pricing strategy by setting
• Safety-driven adoption limits (monitoring requirements, contraindications)

Competitive landscape package

• Competitor list and their formulary position
• Key differentiators that influence prescribing behavior in acute care

---

Key Takeaways

• A complete clinical-trials update and market projection for etripamil cannot be produced from the information available in the prompt to the required accuracy standard.
• A numbers-based market model requires etripamil’s indication(s), trial outcomes, dose/utilization, and price/net reimbursement assumptions.
• Decision-grade analysis for investors and R&D teams should start with the trial record and indication-specific revenue drivers, then map penetration to hospital uptake mechanics.

---

FAQs

1. What is the fastest way to build an etripamil market model?
   Build from indication-specific treated population, then apply penetration tied to trial endpoints and hospital protocol adoption.

2. What endpoints matter most for IV cardiovascular agents like etripamil?
   Time-to-effect and clinically meaningful rhythm or rate control endpoints, paired with safety outcomes that affect protocol adoption.

3. How do competitors typically limit adoption of new acute arrhythmia agents?
   Existing agents with guideline support, established dosing familiarity, and formulary coverage in ED, ICU, and inpatient telemetry settings.

4. What pricing factor most impacts revenue for acute inpatient drugs?
   Net price at the site-of-care level and how payers reimburse inpatient vs ED/observation utilization.

5. What signals in clinical trials most affect guideline inclusion?
   Consistent efficacy across patient subgroups, robust safety signals, and clear superiority or non-inferiority versus standard comparators on endpoints that translate to clinical workflow.

---

References

[1] No sources were provided in the prompt.